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KAJIAN KESAN EKSPRESI BERLEBIHAN OTUB1 PADA BARAH SERVIKAL 
MANUSIA HeLa  
 
ABSTRAK 
Protein ubiquitinasi adalah proses regulasi yang mengawal  kebanyakan mekanisma 
fisiologi dan patologi dan yang melibatkan perkembangan tumor. Enzim deubiquitinasi 
(DUBs) semakin diterima bahawa ia bermutasi pada kanser manusia dan mempunyai 
peranan sebagai onkogen dan penahan tumor. Kajian terdahulu mendapati DUBs 
mengawal proses yang berkaitan dengan proliferasi sel dan apoptosis, menjadikan ia 
sasaran untuk terapi kanser. Dalam kajian ini, kami ingin mengkaji sama ada tumor 
ovari protease (OTU) iaitu dalam keluarga DUBs mempengaruhi sel proliferasi sel 
HeLa. Kami melakukan kajian kesan ekspresi berlebihan pada kanser servikal HeLa dan 
sel L929. Tranfeksi dilakukan menggunakan Lipofectamine™3000 pada kedua-dua sel. 
Kecekapan transfeksi diukur menggunakan mikroskop fluorescence. Ujian MTT 
dijalankan untuk melihat proliferasi sel HeLa dan L929. Analisis statistic dijalankan 
menggunakan  ujian ANOVA satu hala. OTUB1 secara signifikan membantut 
pertumbuhan sel HeLa pada semua masa inkubasi jika dibandingkan dengan sel 
kawalan. Kesimpulannya, ekspresi berlebihan OTUB1 membantut proliferasi sel HeLa. 
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THE EFFECT OF OTUB1 OVEREXPRESSION ON HUMAN CERVICAL 
CANCER HeLa 
 
ABSTRACT 
 
Protein ubiquitination is a highly regulated process that controls multiple physiologically 
and pathologically relevant mechanisms involved in tumor development. There is 
growing recognition that mutated deubiquitinating enzyme (DUBs) in human cancers 
suggesting their roles as oncogenes and tumor suppressors. Previous studies have 
identified the DUBs regulate processes associated with cell proliferation and apoptosis, 
and as such represent candidate targets for cancer therapeutics. Here we investigated 
whether members of the ovarian tumor proteases (OTU) family of DUBs influence the 
proliferation in HeLa cells. We intended to study the effect of OTUB1 overexpression in 
cervical cancer HeLa and L929 cells lines. Transfection with Lipofectamine™ 3000 was 
performed in both cell lines. The transfection efficiency was measured by fluorescence 
microscopy. MTT assay was performed to evaluate cell proliferation on HeLa and L929 
cells. Statistical analysis was performed by using one way ANOVA test. OTUB1 has 
significantly inhibit the proliferation of Hela cells at all incubation times in comparison 
to control. In conclusion, overexpression of OTUB1 inhibit the cell proliferation of 
HeLa. 
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CHAPTER 1 
INTRODUCTION 
1.1 Research background 
Cervical cancer is a cancer in tissues of the cervix. It is usually a slow growing 
cancer that may not have symptoms but can be found with regular pap tests. Most cervical 
cancer cases (83%) occur in developing countries in which they account for 15% of female 
cancers, compared to 3.6% in developed regions (Gakidou et al., 2008). Cervical cancer is 
the third most frequent cancer in women after breast and colorectal cancers and is one of 
the leading causes of cancer death among women in the world (Ferlay et al., 2010). 
According to Globocan statistics (2012) in Malaysia, about 2,145 new cervical cancer cases 
are diagnosed annually. Cervical cancer ranks as the second cause of female cancer in 
Malaysia and the second most common female cancer in women aged 15 to 44 years in 
Malaysia. Compared among the major races, Chinese women had the highest incidence for 
cervical cancer followed by the Indians and Malays (National Cancer Registry, 2006). 
Therefore, there is critical need for better targeted therapies for cervical cancer. 
 OTUB1 is a member of OTU family which are part of deubiquitinating enzymes 
(DUBs) family. It is establish for its deubiquitinating properties (Messick et al., 2008). 
They play an important role in many physiological and pathological process such as 
interferon signaling (Huang et al., 1995 ;Sass et al., 1995 ; Li et al., 2014). DUBs has been 
reported regarding an association with cancer as it found mutated in human cancer 
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suggesting their roles as oncogenes and tumor suppressor genes. DUBs also found to play 
crucial aspect in regulating cell proliferation (Hussain et al., 2009). 
There are approximately 100 identified OTU family members of proteins from 
eukaryotes, viruses and pathogenic bacteria (Balakirev et al., 2003). It is include OTUB1, 
OTUB2, YOD1 and OTULIN. Previous study has shown that OTUB1 mediates certain 
types of cancer such as prostate cancer cell invasion through RhoA activation and promotes 
tumorigenesis in vivo (Iglesias-Gato et al., 2015). OTUB1 also interact with ERα which is 
key factor involved in the development of breast and endometrial cancers in cells and in 
vitro (Stanišić et al., 2009). Previous literature shows that OTUB1 from ovarian tumor 
(OTU) family has been identified as a novel p53 regulator. There are an evidence show that 
overexpression of OTUB1 cause apoptosis and inhibition of cell proliferations in a p53 
dependant manner (Sun et al., 2011).  
As a result of these finding, OTU family members rise as a promising regulator in 
cancer associated pathway, human DUBs are increasingly regarded as a potential drug 
target including cancer and neurodegeneration disease (Pfoh et al., 2015). However, most 
of the research activities in OTU family are still limited.  It could be interesting to see 
overexpression of OTUB1 in cervical cancer using HeLa cell lines as the role of OTUB1 in 
this disease has still not been fully elucidated.  
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1.2 Objective of the study 
The aim of present study is to study overexpression of OTUB1 could significantly 
enhance or inhibit proliferation of cancer cells in vitro. The specific study were : 
1)   To transfect and express OTUB1 clones in human cancer cell lines HeLa and 
mouse fibroblast L929. 
2) To assess the effect on proliferation of human cancer cell lines upon 
overexpression of OTUB1 protein by MTT assay. 
  
 1.3 Hypothesis of the study 
The expected outcomes of the study were : 
1)   Overexpression of OTUB1 could significantly promote proliferation of cancer 
cells in vitro or inhibit proliferation of cancer cells in vitro. 
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CHAPTER II 
LITERATURE REVIEW 
 
2.1 Cancer Statistic 
An estimated 14.1 million new cancer cases and 8.2 million cancer-related deaths 
occurred in 2012, compared with 12.7 million and 7.6 million, respectively, in 2008. In 
year 2012, there were 32.6 million people (over the age of 15 years) alive who had a cancer 
diagnosed in the previous five years (World Health Organization, 2013). 
The most commonly diagnosed cancers worldwide were those of the lung (1.8 
million, 13.0% of the total), breast (1.7 million, 11.9%), and colorectum (1.4 million, 
9.7%). The most common causes of cancer death were cancers of the lung (1.6 million, 
19.4% of the total), liver (0.8 million, 9.1%), and stomach (0.7 million, 8.8%) (World 
Health Organization, 2013).  
Worldwide, cervical cancer is second only to breast cancer as the most common 
female malignancy in both incidence and mortality, and results in approximately 275000 
deaths annually  (Parkin et al., 2005). Some 83% of the cases occur in developing 
countries, where cervical cancer accounts for 15% of female cancers, with a risk before age 
65 of 1.5%, while in developed countries it accounts for only 3.6% of new cancers, with a 
cumulative risk (ages 0–64) of 0.8% ( Ferlay  et al., 2004). 
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2.2 Protein Ubiquitination 
Protein ubiquitination is a highly regulated process that controls multiple 
physiologically and pathologically relevant mechanisms involved in tumor development. 
The degree of ubiquitination of specific proteins is controlled by the concerted actions of 
E3 ubiquitin ligases, deubiquitinating enzymes (DUBs) and the proteasome (Deshaies RJ & 
Joazeiro CA., 2009; Komander D et al., 2009). 
The attachment of ubiquitin to target proteins is mediated by an enzymatic cascade 
consisting of E1 (ubiquitin-activating enzyme), E2 (ubiquitin-conjugating enzymes), and 
E3 (ubiquitin-protein ligases) proteins (Fang & Weissman 2004). The existence of a large 
number (N500) of E3 ligases makes them the main specificity factor in the UPS. Target 
proteins may be monoubiquitinated or, as in this example, polyubiquitinated. A target 
protein must be tagged with at least four ubiquitin monomers (forming a polyubiquitin 
chain) to be recognized by the proteasome. DUBs, are components of the UPS that catalyze 
the removal of ubiquitin moieties from target proteins or polyubiquitin chains, resulting in 
altered signaling or changes in protein stability (D’Arcy et al., 2015). 
Human genome encodes approximately 95 putative DUBs, grouped into five 
families: Ub-specific protease (USP), Ub C-terminal hydrolase (UCH), ovarian tumour 
(OTU) domain-containing protease, Machado–Joseph disease (MJD) protease, and 
JAB1/MPN/Mov34 metalloenzyme (JAMM) (Nijman et al., 2005). 
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The ubiquitin–proteasome system (UPS) has many critical regulatory roles in 
eukaryotic cellular processes including cell cycle progression, stress response, signal 
transduction, transcriptional activation, and DNA repair (Ciechanover et al., 2000; 
Ciechanover 2006).  
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Figure 2.1: Ubiquitination of proteins. Proteins are targeted for degradation by the addition 
of ubiquitin chains to lysine residues by a process that involves three enzymes, E1,E2 and 
E3. DUBs catalyze the removal of ubiquitin moieties from target proteins or polyubiquitin 
chains, resulting in altered signaling or changes in protein stability.  (D’Arcy et al., 2015). 
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2.3 DUB and cancer pathway 
Oncogenes and tumor suppressors act at various points along the signal transduction 
pathway between the plasma membrane and the nucleus affecting mitogenic processes in 
ways that either enhance or slow cell growth. Given the pervasive role of ubiquitin DUBs 
and cancer mediated signaling or targeted proteolysis in these pathways, it is not surprising 
to find that DUBs play critical roles in regulating cell proliferation (Hussain et al., 2009).  
Ubiquitination of oncoproteins and tumour suppressors can promote their 
destabilization by targeting them for degradation (e.g., K48-linked poly-ubiquitination 
specifies proteasomal degradation), or regulate their activity (activation or inactivation). 
Activation here may refer to a variety of processes like translocation to the nucleus (e.g 
PTEN and FOXO), or engagement in signalling protein interaction networks (TRAF6, 
RIP1). Specific DUBs implicated in tumourigenesis. Previous study by Iglesias-Gato et al., 
2015 demonstrated that OTUB1 is overexpressed in prostate cancer suggests a role for 
OTUB1 in tumorigenesis and invites additional exploration of its mechanisms of action. 
The ubiquitin proteasome pathway is intricately involved in nearly all aspects of 
cell biology. Ubiquitination is covalent attachment of the small protein modifier ubiquitin 
to a substrate protein is involved in virtually all cellular processes by mediating the 
regulated degradation of proteins. Deubiquitination is have been shown to play a role in the 
cleavage of ubiquitin from translational precursors and in the maintenance of free ubiquitin 
levels within the cell by the deubiquitinating enzymes (or DUBs). However, DUBs can also 
remove both monoubiquitin and polyubiquitin chains from proteins, or can trim the distal 
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ubiquitin from polyubiquitin chains. Consequently, these activities can potentially 
antagonize the functions of ubiquitination within the cell (Komander et al, 2009). 
Deubiquitination plays an equally important regulatory role as well as ubiquitination. There 
is a growing list of human cancers in which direct mutational alterations in DUBs has been 
observed. Much more work is required in order to fully appreciate the role of 
deubiquitination in malignancy (Hussain et al., 2009). 
  
10 
 
 
 
Figure 2.2. Deubiquitinases are important regulators of oncogenes and tumour suppressors. 
Both overexpression and loss of function of DUBs can promote cancer (Sacco et al., 2010). 
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2.4 OTUB1 
Ovarian-tumor-domain-containing proteases (OTUs) are part of the deubiquitinating 
enzymes (DUBs) family (Makarova et al., 2000 ; Edelmann M, 2009). One of the most 
recently recognized DUBs is the OTUs. This family mainly comprises a group of putative 
cysteine proteases including OTUB1, OTUB2, A20 and yeast OTU1 (Edelmann M, 2009). 
  OTUB1 was the first member of OTU family to be confirmed for its 
deubiquitinating properties. It is located at chromosomal position 11q13.1, and is 
ubiquitously expressed in human tissues such as in kidney tissue (Messick  et al., 2008 ; 
Zhang et al., 2012). 
OTUB1 is thought to play an important role in many physiological and pathological 
processes of human being. The OTUB1 gene product is identified to be involved in the 
control of cell division and differentiation of the cystoblast into an oocyte and nurse cells  
(Huang YZ et al. 1995; Sass et al., 1995).  
Although widely expressed, OTUB1 was specifically implicated in mediating 
lymphocyte antigen responsiveness through affecting the stability of the lymphocyte-
specific E3 ligase GRAIL (gene related to anergy in lymphocytes) in CD4+ T-lymphocytes 
(Soares L et al., 2004). Moreover, OTUB1 was also found in Lewy bodies of the brain on 
mass spectrometry, and may be involved in the pathogenesis of neurodegenerative 
disorders (Xia Q et al., 2008). 
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OUT 
DUB 
name 
 
Mutation/translocation 
Published 
abnormalities/protein 
level 
Oncomine 
Upregulation Downregu-
lation 
 
OTUB1 
 
None reported 
 
None reported 
 
Bladder/lung,pr
ostate, HNSCC, 
breast 
Brain, 
HNSCC, 
testis, 
cervical, 
sarcoma 
A20 Chromosomal deletions and 
inactivating mutations 
found in several lymphoma 
subtype. 2 out 11 lung 
cancer 
Study showing 
overexpression in 
Hodgkins and anaplastic 
B-cell lymphomas with 
downregulation in other 
lymphoma types 
HNSCC, 
luekemia, lung, 
brain, cervical. 
Bladder, 
ovary, lung, 
lymphoma, 
sarcoma 
Cezanne None reported None reported Liver, myeloma Ovarian 
TRABID 1/202 kidney cancer None reported Brain, 
testiscular, 
leukemia 
Oesophagus, 
liver 
Brain, 
leukemia, 
liver, 
testicular, 
bladder 
 
Table 1.1: Example of OTU DUBs including OTUB1 that have mutation and altered 
expression in cancer cell lines, listed from COSMIC (Catalogue of Somatic Mutations in 
Cancer) and Oncomine database.  (Sacco et al., 2010) 
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2.5 Therapeutic application of ubiquitination 
Key cancer-associated proteins whose levels are tightly controlled by the ubiquitin 
proteasome include p53, p27, cyclins and BCL2 family members. The enzymes involved in 
conjugation and deconjugation of ubiquitin to protein substrates include an activating ATP 
dependent ubiquitin enzyme (E1), an ubiquitin-conjugating enzyme (E2), ubiquitin-protein 
ligases (E3s) that often form multi-component complexes key for substrate recognition, and 
deubiquitinases (DUBs) that cleave ubiquitin from protein substrates. In humans, there are 
just a few E1 enzymes, around 40 E2 enzymes, over 500 E3 ligases (most commonly RING 
and HECT domain E3s) and around 100 DUBs, the majority belonging to the ubiquitin-
specific protease (USP) sub-family (Lipkowitz & Weissman 2011, Budhidarmo et al., 
2012, Jacq et al., 2013). 
These enzymes have major regulatory roles in normal cellular processes, both 
within and independently of the ubiquitin-proteasome, including DNA repair, maintaining 
genomic stability and transcription. Aberrant expression of a number of DUBs and E3s has 
been linked to cancer (Lipkowitz & Weissman 2011 ;Clague et al., 2013). As a 
consequence, many of these enzymes are generating extensive interest as targets for the 
treatment of cancer (Marsh 2015). 
Several DUBs have been implicated in various diseases, including neurological 
disorders, infectious diseases and cancer. A genome-wide RNAi (RNA interference) screen 
of the catalytically active human USPs in cancer-relevant cellular models and phenotypic 
assays was performed to identify potential USP targets in cancer (Colland, F. 2006). 
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2.6 Targeting p53 as anticancer therapy 
p53 plays a critical role in tumor suppression mainly by inducing growth arrest, 
apoptosis, and senescence, as well as by blocking angiogenesis. In addition, p53 generally 
confers the cancer cell sensitivity to chemoradiation. Thus, p53 becomes the most 
appealing target for mechanism-driven anti-cancer drug discovery. The approaches 
currently undertaken to target p53 and its regulators with an overall goal either to activate 
p53 in cancer cells for killing or to inactivate p53 temporarily in normal cells for 
chemoradiation protection. The compounds that activate wild type (wt) p53 would have an 
application for the treat- ment of wt p53-containing human cancer. Likewise, the 
compounds that change p53 conformation frommutant to wt p53 (p53 reactivation) or that 
kill the cancer cells with mutant p53 using a synthetic lethal mechanismcan be used to 
selectively treat human cancer harboring a mutant p53. The inhibitors of wt p53 can be 
used on a temporary basis to reduce the normal cell toxicity derived from p53 activation. 
Thus, successful development of these three classes of p53 modulators, to be used alone or 
in combination with chemoradiation, will revolutionize current anticancer therapies and 
benefit cancer patients (Wang & Sun 2010). 
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2.7 Regulations of p53 by OTUB1  
The ubiquitin (Ub) proteasome system plays a pivotal role in the regulation of p53 
protein stability and activity. p53 is ubiquitinated and destabilized by MDM2 and several 
other Ub E3s, whereas it is deubiquitinated and stabilized by Ub-specific protease (USP)7 
and USP10. 
According to study by Sun et al., (2011) OTUB1 is a novel p53 regulator. OTUB1 
directly suppresses MDM2-mediated p53 ubiquitination in cells and in vitro. 
Overexpression of OTUB1 drastically stabilizes and activates p53, leading to apoptosis and 
marked inhibition of cell proliferation in a p53-dependent manner. 
Under physiological conditions, p53 is maintained at low levels primarily by the 
oncoprotein MDM2. MDM2 also promotes p53 ubiquitination and degradation through the 
proteasome system (Haupt et al, 1997; Kubbutat et al, 1997). Together, their results suggest 
that OTUB1 have a novel function in regulating p53 stability and activity. 
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CHAPTER III 
MATERIALS AND METHODS 
3.1 Introduction 
The major requirement is to maintain an aseptic work area that is restricted to cell culture 
work. The procedure must be performing in a designated cell culture including sterile 
handling, incubation, and storage of cell cultures, reagents, and media. The simplest and 
most economical way to provide aseptic conditions is to use a cell culture hood (biosafety 
cabinet). All material need in this study including glassware and plasticware were sterelize. 
Autoclavable materials were autoclaved at 121 °C for 30 minutes at the pressure of 100 
kPA prior to use. 
3.2 Preparation of Cells 
3.2.1 Cell line 
Two cell lines were chosen in this study which is HeLa cell lines and L929 mouse 
fibroblast. L929 mouse fibroblast was selected as it represent normal cell. Both cell lines 
were maintain in the same medium. Dulbecco’s Modified Eagle Medium (DMEM) (Gibco, 
USA) medium was used to culture HeLa (American Type Culture Collection ATCC, USA) 
and L929 ( Life technology, USA)  in suspension and supplemented with 10% (v/v) Fetal 
Bovine Serum (FBS) (Gibco, USA), 1% (v/v) Penicillin-Streptomycin (Gibco, USA). 
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Centrifugation was done at 500 × g for 10 minutes after the collection of cells in log phase 
of growth.  
3.2.2 Thawing of HeLa Cells 
The cryopreserved HeLa and L929 cells were taken out from a liquid nitrogen tank and 
immediately soaked in a water bath at 37°C until cells become semi fluid. The cells were 
transferred into a 15ml tube (BD Biosciences, USA) containing 5 ml of prewarmed 
complete DMEM (Gibco, USA) and mixed gently. The cells suspension was centrifuged at 
500 x g for 10 minutes. The supernatant of DMSO then discarded and the pellet was 
resuspended with pre-warmed complete DMEM growth medium. The cells suspension was 
transferred into 25 cm2 tissue culture flask. Then the cells suspension was incubated at 
37°C in 5% CO2. Cells were routinely checked under inverted microscope to determine the 
confluence of cells growth. The cells were subculture when the cells reached 70 to 80% 
confluent of cell growth. 
3.2.3 Subculturing of Cell lines 
HeLa and L929 cells were detached from the flask by incubating 1 ml of trypsin express 
(Gibco, USA) for 5 to 10 minutes in 5% CO2 air at 37 °C. Then the flask was gently tapped 
to detached the cells from the wall of flask. The floating cells were transferred into the 15 
ml tube and centrifuged for 10 minutes at 500 × g. The supernatant was discarded and the 
pallet was resuspended with complete DMEM growth medium. The cells were transferred 
into flask and incubated in an incubator at 37 °C in 5% CO2. 
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3.3 pEGFP-N1-OTUB1 Vector Information 
pEGFP-N1 is used to insert genes of interest, OTUB1.  It encodes a red-shifted variant of 
wild-type GFP  which has been optimized for brighter fluorescence and higher expression 
in mammalian cells. pEGFP-N1 encodes the GFPmut1 variant which contains the double-
amino-acid substitution of Phe-64 to Leu and Ser-65 to Thr. The coding sequence of the 
EGFP gene contains more than 190 silent base changes which correspond to human codon-
usage preferences. The MCS in pEGFP-N1 is between the immediate early promoter of 
CMV (P CMV IE) and the EGFP coding sequences. Genes cloned into the MCS will be 
expressed as fusions to the N-terminus of EGFP if they are in the same reading frame as 
EGFP and there are no intervening stop codons. SV40 polyadenylation signals downstream 
of the EGFP gene direct proper processing of the 3' end of the EGFP mRNA. The vector 
backbone also contains an SV40 origin for replication in mammalian cells expressing the 
SV40 T antigen. A neomycin-resistance cassette (Neor), consisting of the SV40 early 
promoter, the neomycin/kanamycin resistance gene of Tn5, and polyadenylation signals 
from the Herpes simplex virus thymidine kinase (HSV TK) gene, allows stably transfected 
eukaryotic cells to be selected using G418. A bacterial promoter upstream of this cassette 
expresses kanamycin resistance in E. coli. The pEGFP-N1 backbone also provides a pUC 
origin of replication for propagation in E. coli and an f1 origin for single-stranded DNA 
production. 
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Figure 3.1 Vector information of pEGFP-N1-OTUB1 
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3.4 Transfection using Lipofectamine ™ 3000 
Cells were transfected at high cell density. One day before transfection, Cells were plated 
0.5-2 x 10x 5 cells in 500 µl of growth medium without antibiotics so that cells will be 90 
to 95% confluent at the time of transfection for high efficiency, high expression levels, and 
to minimize cytotoxicity. Complexes were prepared using a DNA (µg) to Lipofectamine™ 
3000 (µl). Opti-MEM medium were used to dilute Lipofectamine™ 3000 and DNA before 
complexing.  Add diluted DNA to diluted Lipofectamine™ 3000 Reagent (1:1 ratio). DNA 
concentration should contain 0.1 ng/ml in each well. But DNA stock available For HeLa 
cells is 495 ng/ml. So each well of treated cell contain 0.2 µl of DNA. In L929 cells,  683.3 
ng/ml were used and each well of treated cell were contain 0.15 µl of DNA. Incubate for 5 
minutes at room temperature. After 5 minute incubation, combined diluted DNA with 
diluted Lipofectamine™ 3000. Mix gently and incubate at 37°C for 4 days and continue 
with viability assays. 
3.5  Transfection efficiency analysis 
Proliferation of HeLa cells and L929 cells in response to the OTUB1 overexpression were 
were identified by fluorescence microscopy for expression of the OTUB1. Transfections 
were identified by using Green Fluorescent Protein (GFP) as reporter gene. 
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3.4 Viability assays 
3.4.1 Reagent Preparation 
Proliferation of HeLa cells and L929 cells in response to the OTUB1 overexpression was 
assessed by using MTT assays and the cell number determined by using standard 
microplate absorbance readers. The protocol of MTT assay was performed according to the 
method of developed by Mossman T (1983). 12 mM MTT stock solution were prepared by 
adding 1 mL of sterile PBS to one 5 mg vial of MTT (Component A). The solution were 
mix by vortexing or sonication until dissolved. Some particulate material that will not 
dissolve is removed by filtration or centrifugation. Component B were prepared by add 10 
mL of 0.01 M HCl to one tube containing 1 gm of SDS. The solution gently dissolves by 
inversion or sonication. Once prepared, the solution should be used promptly. Cell were 
treated with complex Opti-MEM medium, Lipofectamine ™ 2000, Lipofectamine ® 2000 
Reagent. Cell were analysed in 0 hour, 12 hour, 24 hour and 48 hour. Cells seeded at 
densities between 5000 to 10,000 cells per well.  The medium were removed and replace 
with 100 µL of fresh culture medium. 10 µL of the 12 mM MTT stock solution were added 
to each well. 10 µL of the MTT stock solution also were added to 100 µL of medium of 
negative control. Microplate were incubate for 4 hours. After that 100 µL of the SDS HCl 
solution were added to each well and mix thoroughly using the pipette. Microplate were 
incubate again at 37°C for 4 to 18 hours . Samples were mix again using a pipette and 
absorbance were read at 570 nm.   
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3.5 Statistical Analysis 
The representative data were presented as mean ± SEM. Statistical analysis was performed 
using IBM SPSS Statistic Version 2.0. The comparison between control and treated was 
tested for significance using one way ANOVA. Differences at p <0.05 were considered to 
be statistically significant. 
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3.6 Flow chart of study 
HeLa cancer cell lines and L929 cell lines: 
Growth in DMEM medium supplemented with 10% fetal bovine serum 
and penicillin-streptomycin solution 
   ↓ 
Sub-culturing cell culture, and live cell count determined using a haemocytomer 
 ↓ 
 ↓ 
↓ 
 
↓ 
 
 
  
Transfection of pEGFP-N-OTUB1 on HeLa cells and L929 cells using 
lipofectamine ™ 3000  
Transfection efficiency by fluorescence microscopy 
MTT assay to evaluate cell proliferation 
Statistical analysis 
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CHAPTER IV 
RESULT 
 
4.1 Transfection of pEGFP-N-OTUB1  
4.1.1 Transfection of  pEGFP-N-OTUB1 on HeLa cells 
HeLa cancer cell lines were transfected with plasmid containing pEGFP-N1-OTUB1 in 96 
well plates at 70% confluent. Cells were transfected by vectors with  Lipofectamine™  
3000  following  the  manufacturer’s  protocol. Transfection were performed using an 
appropriate concentration of DNA and 5 μL of Lipofectamine™ 3000 Reagent. Clones 
were identified by fluorescence microscopy for expression of the OTUB1. Transfections 
were identified by using Green Fluorescent Protein (GFP) as reporter gene. 
 
 
 
 
 
 
 
 
 
